Bisphosphonate News and Research

RSS

Bisphosphonate is a drug or substance used to treat hypercalcemia (abnormally high blood calcium) and bone pain caused by some types of cancer. Forms of bisphosphonates are also used to treat osteoporosis and for bone imaging. Bisphosphonates inhibit a type of bone cell that breaks down bone. Also called diphosphonate.

New contrast agent selectively targets and highlights malignant micro-calcifications in the breast

Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.

2 Apr 2007

Male sufferers now have access to osteoporosis drug Actonel

The U.S. Food and Drug Administration (FDA) has given it's approval for the drug Actonel (risedronate sodium) to be used to treat osteoporosis in men.

15 Aug 2006

Osteonecrosis of the jawbone and oral bisphosphonates

People taking oral bisphosphonates, a type of drug used to treat osteoporosis, osteopenia and Paget's disease of bone, should be aware of potential risks when undergoing certain dental procedures, according to guidelines published in this month's Journal of the American Dental Association (ADA).

4 Aug 2006

Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy

The patient of a periodontist in private practice in New Orleans developed osteonecrosis of the jaw (ONJ), a condition that can cause severe, often irreversible and debilitating damage to the jaw, following periodontal surgical therapy.

11 Apr 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006

Bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy

In a small study from a referral center for dermatology, most patients receiving prolonged oral corticosteroids for chronic skin diseases were not receiving therapies to prevent osteoporosis that may be caused by the drug, according to an article in the January issue of Archives of Dermatology.

16 Jan 2006

Risedronate prevents bone loss and periodontal disease

Drugs that reverse and prevent bone loss due to osteoporosis also significantly ward off periodontal disease, according to a graduate of the Case Western Reserve University School of Dental Medicine who reports in the current Menopause journal article, "Periodontal Assessments of Postmenopausal Women Receiving Risedronate."

7 Dec 2005

Women with postmenopausal osteoporosis prefer once monthly to weekly treatment

Over 70% of postmenopausal women with Osteoporosis who expressed a preference, preferred once-monthly Bonviva, finding it more convenient than a once-weekly treatment. This is according to new data presented at the 27th Annual Meeting of the American Society for Bone Mineral Research (ASBMR).

26 Sep 2005

85 percent of postmenopausal women do not get enough calcium

An analysis presented today at the 27th Annual Meeting of The American Society for Bone and Mineral Research found that 85 percent of postmenopausal women do not get enough calcium on a daily basis.

26 Sep 2005

Alendronate combined with calcium and vitamin D almost completely prevented further bone loss in the first 4 months afte liver transplant

A new study found that the drug used to treat osteoporosis, when used in combination with calcium and vitamin D, can prevent the additional bone loss that commonly occurs after liver transplants. The treatment also helped stabilize bone loss in patients who already had osteoporosis, and helped improve their bone mineral density (BMD).

20 Jul 2005

$New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer$

New protective drugs called bisphosphonates reduce pain and fractures in metastatic breast cancer

When breast cancer spreads to bones, relatively new protective drugs called bisphosphonates can reduce skeletal damage, says a new systematic review of previous studies. While the new treatment approach does not improve survival rates, it can minimize disabling fractures, spinal cord compression and pain.

19 Jul 2005

Bone Medical completes first trial of oral parathyroid hormone product for treatment of osteoporosis

Bone Medical Ltd announced today the completion of a Phase I trial of its oral parathyroid hormone (PTH) product Perthoxal™ under development for the treatment of osteoporosis.

3 Jul 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Calcium crucial to benefits of osteoporosis drugs

Although an increasing number of people are taking powerful new prescription drugs to treat osteoporosis, chances are the majority of patients are not getting the greatest effect from these medicines because they do not have an adequate calcium and vitamin D intake, according to a paper published in the March 2005 issue of The Journal of Women's Health.

23 Mar 2005

$Screening for osteoporosis in men and women age 65 and older can prevent a large number of hip fractures$

Screening for osteoporosis in men and women age 65 and older can prevent a large number of hip fractures

Researchers at Johns Hopkins have determined that screening for osteoporosis in men and women age 65 and older can prevent a large number of hip fractures, a debilitating, traumatic experience for 340,000 older adults annually.

31 Jan 2005

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Doctors at Long Island Jewish (LIJ) Medical Center recently discovered a link between a common chemotherapy drug and a serious bone disease called osteonecrosis of the jaw (ONJ).

13 Dec 2004

Silent risk of osteoporosis in men with prostate cancer

Men being treated for prostate cancer using hormone therapy maybe under-recognized for their risk of developing osteoporosis, according to a new study.

13 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Major bone trial to test high dose corticosteroid steroid tablets

Researchers in Aberdeen are about to launch a major multi-centre clinical trial to test whether a new drug could prevent bone thinning in adults taking moderate to high dose corticosteroid "steroid" tablets, such as prednisolone.

8 Nov 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004